Click here to

  1. Home
  2. Meeting Program
  3. Keywords

Search by Keywords

DISCLAIMER:
Entry of taxonomy/keywords during proffered abstract submission was optional.
Not all abstracts will appear in search results.

3 | A | B | C | D | E | F | G | H | I | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | show all

Keywords: nuclear medicine
PO-GePV-M-356A Practical Approach for Improving Quantitative Assessment of Native Renal Recovery Using Multi-View Tc-99m DTPA Renal Scintigraphy for SLK Patients with 3+ Kidneys
J Zhang1*, (1) Radiology, The Ohio State University, Columbus, OH
PO-GePV-T-17Administration of 177Lu-PSMA-617 as Compared to 177Lu-Dotatate
P Patel1*, K McCall1, (1) Henry Ford Health System, Detroit, MI
SU-E-202-2Commissioning of a Commercial Whole-Body Gamma Camera Image-Based Radiopharmaceutical Therapy Treatment Planning System
W Erwin1*, (1) UT MD Anderson Cancer Center, Houston, TX
SU-E-202-5Impact of Dosimetry Method On Organ and Tumor Absorbed Dose Estimates in Lutetium-177-DOTATATE Therapy of Neuroendocrine Tumors
J Brosch-Lenz1*, A Rahmim1; 2; 3, C Uribe2; 3, (1) BC Cancer Research Institute, Vancouver, BC, CA, (2) University of British Columbia, Vancouver, BC, CA, (3) BC Cancer, Vancouver, BC
SU-F-202-2A Method for Partial Volume Correction of Dose Distributions Derived From PET-Based Theranostic Dosimetry
IR Marsh1*, TJ Bradshaw2, JJ Grudzinski2, R Hernandez2, E Aluicio-Sarduy2, BP Bednarz2, (1) Johns Hopkins University, Baltimore, MD, (2) University of Wisconsin-Madison, Madison, WI
TH-B-202-6Time-Dependent Monte Carlo Simulation for Patient-Specific Dosimetry in Radioactive Iodine Therapy
J Shin1*, Y Seo2, Y Li2, R R Flavell2, C Kitahara1, C Lee1, (1) National Cancer Institute, Rockville, MD, (2) University of California San Francisco, San Francisco, CA
TU-AB-BRC-0Biomarkers of Response to Radiation and Immune Modulating Therapies for Advanced Cancer Management
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-1Introduction to the Biomarker Landscape
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-2Evolving Paradigm for Assessing Response to Immunomodulatory Therapies
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-3Radiomics of Radiation and Immune Response Patterns
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-4Clinical and Preclinical Imaging of the Immune System
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-5Role of Molecular Diagnostics and Advanced Tumor Tissue Analysis To Guide Optimal Anti-Cancer Treatment
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-6Combining Imaging & Circulating Biomarkers of Response To Personalize Chemo-Immunotherapy and Radiation Therapy
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-AB-BRC-7Panel Discussion
D Mankoff1*, M Farwell1*, R Li2*, A Wu3*, K Schalper4*, S Bowen5*, (1) University of Pennsylvania, Philadelphia, PA, (2) Stanford University, Palo Alto, CA, (3) City of Hope, Los Angeles, CA, (4) Yale University, New Haven, CT, (5) University of Washington, School of Medicine, Issaquah, WA
TU-E-202-0ICRU Report On Dosimetry-Guided Radiopharmaceutical Therapy
G Sgouros1*, K Sjogreen Gleisner2*, R Hobbs3*, Y Dewaraja4*, (1) Johns Hopkins Medical Institute, Ellicott City, MD, (2) Lund University, Lund, SE, (3) Johns Hopkins University, Baltimore, MD, (4) University of Michigan, Ann Arbor, MI
TU-E-202-1Introduction to the ICRU Report On Dosimetry-Guided Radiopharmaceutcal Therapy
G Sgouros1*, K Sjogreen Gleisner2*, R Hobbs3*, Y Dewaraja4*, (1) Johns Hopkins Medical Institute, Ellicott City, MD, (2) Lund University, Lund, SE, (3) Johns Hopkins University, Baltimore, MD, (4) University of Michigan, Ann Arbor, MI
TU-E-202-2Nomenclature and Levels of Prescribing, Recording and Reporting
G Sgouros1*, K Sjogreen Gleisner2*, R Hobbs3*, Y Dewaraja4*, (1) Johns Hopkins Medical Institute, Ellicott City, MD, (2) Lund University, Lund, SE, (3) Johns Hopkins University, Baltimore, MD, (4) University of Michigan, Ann Arbor, MI
TU-E-202-3RBE and Bioeffect Modeling
G Sgouros1*, K Sjogreen Gleisner2*, R Hobbs3*, Y Dewaraja4*, (1) Johns Hopkins Medical Institute, Ellicott City, MD, (2) Lund University, Lund, SE, (3) Johns Hopkins University, Baltimore, MD, (4) University of Michigan, Ann Arbor, MI
TU-E-202-4Implementation Examples
G Sgouros1*, K Sjogreen Gleisner2*, R Hobbs3*, Y Dewaraja4*, (1) Johns Hopkins Medical Institute, Ellicott City, MD, (2) Lund University, Lund, SE, (3) Johns Hopkins University, Baltimore, MD, (4) University of Michigan, Ann Arbor, MI
TU-E-202-5Q & A
G Sgouros1*, K Sjogreen Gleisner2*, R Hobbs3*, Y Dewaraja4*, (1) Johns Hopkins Medical Institute, Ellicott City, MD, (2) Lund University, Lund, SE, (3) Johns Hopkins University, Baltimore, MD, (4) University of Michigan, Ann Arbor, MI
WE-E-202-1Does Lung Shunt Fraction Correlate to Lung Dose in Y90 Radioembolization Treatments? A Study Using Voxel-Based Monte Carlo Dosimetry
M Bobic*, E Wehrenberg-Klee, C Grassberger, H Paganetti, J Schuemann, A Bertolet, Massachusetts General Hospital and Harvard Medical School, Boston, MA
WE-E-202-5BEST IN PHYSICS (THERAPY): Precision Dosimetry in Yttrium-90 Radioembolization Through CT Imaging of Radiopaque Microspheres in a Rabbit Liver Model
E Henry1*, M Strugari2,3, G Mawko2,4,5,6, K Brewer2,3,6,7, D Liu9, A Gordon10, J Bryan11, C Maitz11, R Abraham6,8, S Kappadath1, A Syme2,4,5, (1) Department of Imaging Physics, University of Texas MD Anderson Cancer Centre, Houston, TX, USA, (2) Department of Physics and Atmospheric Science, Dalhousie University, Halifax, NS, Canada, (3) Biomedical Translational Imaging Centre, Halifax, NS, Canada, (4) Department of Medical Physics, Nova Scotia Health Authority, Halifax, NS, Canada, (5) Department of Radiation Oncology, Dalhousie University, Halifax, NS, Canada, (6) Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada, (7) Department of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada, (8) ABK Biomedical Inc., Halifax, NS, Canada, (9) School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada, (10) Department of Radiology, Northwestern University, Chicago, IL, USA, (11) Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
WE-E-202-6Variations in Activity and Dose Calculations in Pre-Treatment Planning for Hepatic Lobar Y-90 Microspheres Therapy When Using Anatomic Versus Functional Imaging Contouring Techniques
D Alvarez1*, L Rodriguez1, R Herrera1, T Kutuk1, E Saugar1, A Kaiser1, M Chuong1, A Gutierrez1, S Kim1, R Gandhi1,2, (1) Miami Cancer Institute, Miami, FL, (2) Miami Cardiac & Vascular Institute, Miami, FL

Share:

Additional Links